#35 Veterinary pharmacovigilance, part 2 – James Mount

Human and veterinary pharmacovigilance (PV) share many goals,
challenges and approaches. But there are also significant
differences, such as the numerous animal species that veterinary
PV needs to take into account. In this two-part episode of Drug
Safety Matters, James Mount, Veterinary Pharmacovigilance
assessor at the Swedish Medical Products Agency, and EU elected
chair of the Pharmacovigilance Working Party for veterinary
medicinal products, joins the show to talk about veterinary PV
practice and its differences and similarities to human PV. 


Tune in to find out


How the types of ADRs reported for animals and humans differ

How the many species and breeds included in veterinary PV
affect the ADR coding 

What the Veterinary Big Data Strategy is



... and much more!


Want to know more?


The public portal of the European Union Veterinary
Pharmacovigilance Database.

One Health – an integrated approach to the well-being of
people, animals and the environment.

A survey of veterinary professionals in Sweden, about
practices and attitudes in relation to ADR reporting.

A review of adverse events in animals and children after
secondary exposure to transdermal hormone-containing
medicines. 

The EMA Big Data strategy for veterinary medicines and Data
quality framework for medicines regulation

Small Animal Veterinary Surveillance Network (SAVSNET) -
University of Liverpool

VetCompass - Royal Veterinary College, RVC

Veterinary good pharmacovigilance practices (VGVP) | European
Medicines Agency (EMA)

Veterinary Dictionary for Drug Regulatory Activities (VeDDRA)
| European Medicines Agency (EMA)






Join the conversation on social mediaFollow us on
Facebook, LinkedIn, X, or Bluesky and share your thoughts about
the show with the hashtag #DrugSafetyMatters.

Got a story to share?We’re always looking for new
content and interesting people to interview. If you have a great
idea for a show, get in touch!

About UMCRead more about Uppsala Monitoring Centre
and how we work to advance medicines safety.